ArticleScientific reports2025
Ameliorative effects of Berberine chloride against 5-fluorouracil-induced cardiotoxicity in Sprague Dawley rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Targeting mitochondrial dysfunction and apoptosis in 5-fluorouracil-induced cardiotoxicity using kaempferol-mediated selenium nanoparticles.Scientific reports · 2026Article
- Research progress on plant polysaccharides in the prevention and treatment of tumors (Review).Oncology reports · 2026Review
- EGCG-mediated selenium nanoparticles protect against 5-fluorouracil-induced cardiotoxicity via Nrf2/Keap1 signaling.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Antiarthritic activities of berberine in a rat model of gouty arthritis.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
5-Fluorouracil (5-FU) is the most commonly used chemotherapeutic agent for solid malignancies. Although it has crucial therapeutic effects, it ranks as the second most cardiotoxic antineoplastic agent. Berberine (BBR) is a quaternary benzylisoquinoline alkaloid with promising antioxidant properties. The current study aimed to assess the palliative effect of BBR on 5-FU-induced cardiotoxicity in rats. Fifty male Sprague Dawley rats were randomly divided into five groups: negative control, which received 2% DMSO orally (PO) for 2 weeks; cardiotoxic, which received a single intraperitoneal (IP) injection of 5-FU (150 mg/kg); groups 3 and 4, which received a single IP injection of 5-FU (150 mg/kg) followed by BBR (50 mg/kg and 100 mg/kg, respectively) PO for 2 weeks; and a BBR-only group, which received BBR (100 mg/kg) PO for 2 weeks. On the 14th day, all groups underwent ECG evaluation. Blood and heart samples were collected 24 h after the last dose for further investigations. 5-FU induced significant alterations in the ECG pattern and caused a significant increase in cardiac troponin I (cTnI), creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH), and malondialdehyde (MDA). Moreover, it led to decreased levels of superoxide dismutase (SOD), reduced glutathione (GSH), and total antioxidant capacity (TAC). Our data suggest that BBR could mitigate 5-FU-induced cardiotoxicity by modulating cardiac injury markers, normalizing cTnI, CK-MB, and LDH levels, reducing oxidative stress by lowering MDA levels, and increasing SOD, GSH, and TAC levels. Additionally, BBR inhibited apoptotic events by suppressing caspase-3 activation and upregulating Bcl-2 expression, reduced the inflammatory response by downregulating cyclooxygenase-2 (COX-2) and tumor necrosis factor-alpha (TNF-α) expression levels, and decreased the risk of thrombosis by increasing endothelial nitric oxide synthase (eNOS) expression levels. In conclusion, BBR exerts ameliorative effects against 5-FU-induced cardiotoxicity in rats.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.